Home  »  Trending   »  Looking Closely at the Growth Curve for Deciphera ...

Looking Closely at the Growth Curve for Deciphera Pharmaceuticals Inc. (DCPH)

Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) went up by 23.88% from its latest closing price compared to the recent 1-year high of $37.99. The company’s stock price has collected 33.10% of gains in the last five trading sessions.

Is It Worth Investing in Deciphera Pharmaceuticals Inc. (NASDAQ :DCPH) Right Now?

Plus, the 36-month beta value for DCPH is at 1.12. Opinions of the stock are interesting as 3 analysts out of 10 who provided ratings for Deciphera Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 5 rated it as “hold,” and 2 as “sell.”

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


The average price from analysts is $10.75, which is -$6.06 below the current price. DCPH currently public float of 47.75M and currently shorts hold a 14.48% ratio of that float. Today, the average trading volume of DCPH was 1.02M shares.

DCPH’s Market Performance

DCPH stocks went up by 33.10% for the week, with a monthly jump of 20.76% and a quarterly performance of 56.08%, while its annual performance rate touched -48.48%. The volatility ratio for the week stands at 9.86% while the volatility levels for the past 30 days are set at 6.57% for Deciphera Pharmaceuticals Inc. The simple moving average for the period of the last 20 days is 27.91% for DCPH stocks with a simple moving average of 42.96% for the last 200 days.

Analysts’ Opinion of DCPH

Many brokerage firms have already submitted their reports for DCPH stocks, with Barclays repeating the rating for DCPH by listing it as a “Underweight.” The predicted price for DCPH in the upcoming period, according to Barclays is $6 based on the research report published on February 28th of the current year 2022.

Stifel, on the other hand, stated in their research note that they expect to see DCPH reach a price target of $10, previously predicting the price at $60. The rating they have provided for DCPH stocks is “Hold” according to the report published on November 08th, 2021.

Canaccord Genuity gave a rating of “Hold” to DCPH, setting the target price at $12 in the report published on November 08th of the previous year.

DCPH Trading at 34.67% from the 50-Day Moving Average

After a stumble in the market that brought DCPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -55.75% of loss for the given period.

Volatility was left at 6.57%, however, over the last 30 days, the volatility rate increased by 9.86%, as shares surge +24.89% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +43.31% upper at present.

During the last 5 trading sessions, DCPH rose by +33.10%, which changed the moving average for the period of 200-days by +98.41% in comparison to the 20-day moving average, which settled at $13.31. In addition, Deciphera Pharmaceuticals Inc. saw 72.06% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at DCPH starting from Sherman Matthew L, who sale 1,768 shares at the price of $10.75 back on Jun 16. After this action, Sherman Matthew L now owns 76,884 shares of Deciphera Pharmaceuticals Inc., valued at $19,006 using the latest closing price.

Martin Daniel C., the Chief Commercial Officer of Deciphera Pharmaceuticals Inc., sale 1,311 shares at $10.75 during a trade that took place back on Jun 16, which means that Martin Daniel C. is holding 49,521 shares at $14,093 based on the most recent closing price.

Stock Fundamentals for DCPH

Current profitability levels for the company are sitting at:

  • -284.85 for the present operating margin
  • +90.23 for the gross margin

The net margin for Deciphera Pharmaceuticals Inc. stands at -311.98. Equity return is now at value -81.40, with -62.10 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 3.50.